Search Results for “AI” – Page 614 – media

FDA sends damning warning letter to Pfizer after misfiring EpiPens linked to deaths

The US Food and Drug Administration(FDA) has sent a damning warning letter to drug giant Pfizer Inc (NYSE:PFE) after it received “hundreds of complaints” that the anti-allergy EpiPen device misfired “during life-threatening emergencies”.
- Source: Proactiveinvestors
- 698
- September 11, 2017
anti-allergy FDA
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 542
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled for 8:30 AM EDT this morning; dial-in and webcast details are provided below.
- Source: Globenewswire
- 3,273
- September 11, 2017
cancer Company Insight T-cell
Teleflex to take over NeoTract for $1.1bn

Teleflex has signed a definitive agreement to purchase NeoTract for approximately $1.1bn. According to the deal, Teleflex will pay $725m worth of cash upfront at closing and up to an additional $375m after the achievement of select commercial milestones associated with sales until the end of 2020.
- Source: medicaldevice-network
- 536
- September 8, 2017
aggrement invasive Market Views
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 745
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL
National Hospitalist Conference

The National Hospitalist Conference will be held in Santa Fe, New Mexico at the Eldorado Hotel & Spa on September 8-10, 2017. The National Hospitalist Conference is designed to provide physicians, physician assistants, and nurse practitioners with information and skills to improve the care of their hospitalized patients.
- Source: medical-events
- 643
- September 8, 2017
Exhibitions & Activities hospitalized
Sanofi wins tentative FDA nod for Admelog insulin lispro injection

Sanofi announced that the U.S. Food and Drug Administration (FDA) granted tentative approval for Admelog® (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analog. Admelog is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Source: yahoo
- 740
- September 7, 2017
Company Insight diabetes FDA insulin New Approvals
Merck KGaA Plans Consumer Healthcare Sale After Strategic Review

Germany's Merck KGaA is looking to sell its $1 billion consumer healthcare unit after a group-wide strategic review.
- Source: thestreet
- 601
- September 7, 2017
Company Insight healthcare Market Views Merck
The World’s Largest and Most Powerful X-Ray Laser Just Went Online

The European XFEL is now online. Built to be the world's largest facility to house the most powerful x-ray lasers that can be produced, the XFEL would contribute to a better understanding of molecular and chemical process by imaging particles.
- Source: Futurism
- 542
- September 7, 2017
molecular x-ray XFEL
Ddu to Attend Expo Medical Expanding the South American Medical Trade Market

The 15th International Show for Products, Equipment and Services for the Healthcare Sector(Expo Medical) will be held at Centro Costa Salguero, Buenos Aires, Argentina from September 27 to September 29, 2017. As the leading global pharmaceutical and medical device B2B online platform, Ddu is going to attend the exhibition along with the products of high priority members and commits itself to the development of the South American medical trade market.
- Source: Ddu
- 821
- September 6, 2017
Exhibitions & Activities Expo Medical medical device pharmaceutical

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.